The prognostic value of microRNA-29a in detecting arrhythmias based on 24-hour electrocardiography monitoring in patients with hypertrophic cardiomyopathy

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

Objective. To assess the prognostic value of circulating microRNA-29a expression levels in relation to cardiac arrhythmias detected by 24-hour (Holter) ECG monitoring in patients with hypertrophic cardiomyopathy (HCM).

Materials and methods. The study included 41 patients with a verified diagnosis of HCM (21 men, 20 women), with a mean age of 57.2±14.2 years. All patients underwent 24-hour ECG monitoring. The expression level of microRNA-29a in plasma was measured using RT-qPCR. The Mann–Whitney U test was used for statistical analysis (p < 0.05).

Results. In patients with arrhythmias, the level of microRNA-29a was significantly lower compared to those without arrhythmias (0.206 vs. 0.433; p = 0.0015). No statistically significant associations were found between miR-29a expression and conduction disturbances.

Conclusion. Reduced expression of microRNA-29a may be associated with an increased risk of arrhythmias in patients with HCM. This epigenetic marker could serve as a valuable addition to existing risk stratification tools and warrants further investigation in larger patient cohorts.

Sobre autores

A. Vysokikh

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Autor responsável pela correspondência
Email: andvusokikh@gmail.com
ORCID ID: 0009-0005-6825-3383
Código SPIN: 7298-1353
Rússia, Moscow

V. Kaplunova

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: andvusokikh@gmail.com
ORCID ID: 0000-0002-5864-0938
Código SPIN: 5326-7363

Professor, MD

Rússia, Moscow

E. Privalova

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: andvusokikh@gmail.com
ORCID ID: 0000-0002-9908-9476

Professor, MD

Rússia, Moscow

Bibliografia

  1. Клинические рекомендации по гипертрофической кардиомиопатии, 2025 [Clinical Guidelines for Hypertrophic Cardiomyopathy, 2025 (in Russ.)].
  2. Maron B.J., Ommen S.R., Semsarian C. et al. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014; 64 (1): 83–99. doi: 10.1016/j.jacc.2014.05.003
  3. O'Mahony C., Jichi F., Pavlou M. et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (ESC Risk Model). Eur Heart J. 2014; 35 (30): 2010–20. doi: 10.1093/eurheartj/eht439
  4. Ommen S.R., Mital S., Burke M.A. et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. Circulation. 2020; 142 (25): e558-e631. doi: 10.1161/CIR.0000000000000937
  5. Шакарьянц Г.А., Кожевникова М.В., Каплунова В.Ю. и др. Взгляд на гипертрофию миокарда с позиции транскриптомики и метаболомики. Кардиология. 2020; 60 (4): 120–9 [Shakaryants G.A., Kozhevnikova M.V., Kaplunova V.Yu. et al. Focus on the Myocardial Hypertrophy from the Perspective of Transcriptomics and Metabolomics. Kardiologiia. 2020; 60 (4): 120–9 (in Russ.)]. doi: 10.18087/cardio.2020.4.n1063
  6. Roncarati R., Anselmi C.V., Losi M.A. et al. Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2014; 63 (9): 920–7. doi: 10.1016/j.jacc.2013.09.041
  7. Rowin E.J., Hausvater A., Link M.S. et al. Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy. Circulation. 2017; 136 (25): 2420–36. doi: 10.1161/CIRCULATIONAHA.117.029267
  8. Yang H. et al. Age-related atrial fibrillation in patients with hypertrophic cardiomyopathy. J Am Heart Assoc. 2014; 3 (6): e001002.
  9. Zhao Y., Yuan Y., Qiu C. Underexpression of CACNA1C Caused by Overexpression of miR-29a-3p in Atrial Fibrillation. Med Sci Monit. 2016; 22: 1975–81. doi: 10.12659/msm.896191
  10. Sassi Y., Avramopoulos P., Ramanujam D. et al. Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling. Nat Commun. 2017; 8 (1): 1614. doi: 10.1038/s41467-017-01737-4
  11. Zhang X., McLendon J.M., Peck B.D. et al. Modulation of miR-29 influences myocardial compliance likely through coordinated regulation of calcium handling and extracellular matrix. Mol Ther Nucleic Acids. 2023; 34: 102081. doi: 10.1016/j.omtn.2023.102081
  12. Balan A.I., Scridon A. MicroRNAs in atrial fibrillation – have we discovered the missing link? Front Pharmacol. 2025; 16: 1535621. doi: 10.3389/fphar.2025.1535621

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).